Tenaya Therapeutics (TNYA) Common Equity (2020 - 2026)
Tenaya Therapeutics (TNYA) posted quarterly Common Equity of $106.2 million for Q1 2026, down 11.06% year-over-year from $119.4 million in Q1 2025, and down 13.85% quarter-over-quarter from $123.3 million in Q4 2025.
Tenaya Therapeutics (TNYA) Common Equity (2020 - 2026) Analysis & Trends
Tenaya Therapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $106.2 million for Q1 2026.
- In Q1 2026, Common Equity fell 11.06% year-over-year to $106.2 million; the TTM figure through Mar 2026 stood at $106.2 million (down 11.06% YoY), while the FY2025 annual figure was $123.3 million, up 32.75% from the prior year.
- Common Equity for Q1 2026 stood at $106.2 million, down from $123.3 million in the prior quarter.
- The five-year high for Common Equity was $249.1 million in Q1 2022, with the low at $82.9 million in Q3 2025.
- The 5-year median for Common Equity is $139.4 million (2023), against an average of $156.0 million.
- The sharpest annual moves came in 2022 and 2023: Common Equity soared 365.16% in 2022, then sank 42.71% in 2023.
- Tenaya Therapeutics' Common Equity stood at $243.4 million in 2022, then tumbled by 42.71% to $139.4 million in 2023, then tumbled by 33.4% to $92.9 million in 2024, then jumped by 32.75% to $123.3 million in 2025, then slipped by 13.85% to $106.2 million in 2026.
- Business Quant data shows TNYA's Common Equity at $106.2 million in Q1 2026, $123.3 million in Q4 2025, and $82.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - | 9.79 Bn |
| 10 | Tenaya Therapeutics | 155.28 Mn | 155.28 Mn | - | 69.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 69.41 Mn |
| Mar 31, 2026 | 106.19 Mn |
| Dec 31, 2025 | 123.27 Mn |
| Sep 30, 2025 | 82.87 Mn |
| Jun 30, 2025 | 99.83 Mn |
| Mar 31, 2025 | 119.40 Mn |
| Dec 31, 2024 | 92.85 Mn |
| Sep 30, 2024 | 112.60 Mn |
| Jun 30, 2024 | 134.00 Mn |
| Mar 31, 2024 | 158.18 Mn |
| Dec 31, 2023 | 139.42 Mn |
| Sep 30, 2023 | 164.88 Mn |
| Jun 30, 2023 | 189.94 Mn |
| Mar 31, 2023 | 215.41 Mn |
| Dec 31, 2022 | 243.38 Mn |
| Sep 30, 2022 | 196.33 Mn |
| Jun 30, 2022 | 223.87 Mn |
| Mar 31, 2022 | 249.10 Mn |
| Dec 31, 2021 | 278.53 Mn |
| Sep 30, 2021 | 303.70 Mn |